Skip to main content
OpenTrials
Completed

NCT Number: NCT04327154

TISSIUM's Nerve Coaptation Device First-in-Human Clinical Trial

The purpose of this study is to collect initial safety and device performance data of the TISSIUM's nerve coaptation device for the sutureless repair of digital nerve injuries of the hand in which there has been no substantial loss of nerve tissue. Additional clinical measures that assess device performance, use, and patient reported outcomes will be collected to guide future study design and potential device modifications.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Princess Alexandra Hospital, Brisbane, Queensland, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient undergoing a repair of a proper digital nerve of the hand;
  • 100% transection injury to the nerve under repair;
  • Gap closure between the nerve ends can be achieved by flexion of the extremity without excessive tension;
  • Clean surgical wound with sufficient healthy soft tissue that enables primary closure without adjunctive soft tissue procedures;
  • Patient willing and able to provide a signed Patient Informed Consent Form;
  • Patient willing and able to follow the study instructions and likely to complete all required study procedures and visits.

Exclusion criteria

  • Patient has a known allergy to the constituent polymer of the investigational device;
  • Patient has a documented diagnosis of peripheral neuropathy;
  • Patient has a history of neuropathic pain;
  • Patient has a history of injury to the nerve being studied;
  • Patient has is missing the contralateral digit or with a history of injury to the contralateral digit (comparison control area);
  • Patient is pregnant or nursing
  • Any patient with a diagnosis of type 1 Diabetes Mellitus;

Treatment and study plan

TISSIUM™ Nerve Coaptation Device

Device

Placement of the TISSIUM™ Nerve Coaptation Device on repair site to achieve an end-to-end nerve coaptation.

Primary outcomes

  1. Cumulative incidence of complications (CIC) related to the investigational device

    Time frame: through 12-months post-procedure

    CIC includes the occurrence of any of the following complications:

    • Infection
    • Chronic pain (defined as pain lasting more than 3 months) not otherwise specified
    • Excessive inflammation as determined by the investigator
    • Device extrusion
    • Symptomatic neuroma formation
    • Impaired wound healing (examples are dehiscence, pain, skin irritation, keloid, scar hypertrophy)
    • Allergic reaction to the constituent polymer of the investigational device
    • Serious Adverse Device Effect (SADEs)

Secondary outcomes

  1. Semmes-Weinstein monofilament (SWMF) for nerve functional recovery

    Time frame: at 6 months post-procedure

    Product performance will be assessed as functional nerve repair based on nerve functional recovery using Semmes-Weinstein monofilament (SWMF) at 6-months post-surgery

Sponsors and collaborators

Lead sponsor

Tissium

Industry

Registry information

Official study title

A Prospective, Multicenter, Single-arm Clinical Trial Evaluating Safety and Performance of TISSIUMTM Nerve Coaptation Device for the Repair of Digital Nerve Discontinuities Where Gap Closure Can be Achieved by Flexion of the Extremity.

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Mar 30, 2020
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.